Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681106 | 0.85 | HSP90AA1 (0.38) | KCNH3PDE4A | |
| SCHEMBL2718827 | 0.77 | NOS3 (0.42) | — | |
| SCHEMBL18652595 | 0.76 | PDE4A (0.36) | KCNH3PDE4A | |
| SCHEMBL24496491 | 0.71 | HSP90AA1 (0.35) | KCNH3PDE4A | |
| SCHEMBL22409600 | 0.71 | HSP90AA1 (0.40) | PDE4A | |
| SCHEMBL8513553 | 0.71 | NOS2 (0.38) | KCNH3PDE4A | |
| SCHEMBL22503007 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL22307825 | 0.69 | FAAH (0.38) | — | |
| SCHEMBL10203026 | 0.67 | SYK (0.38) | KCNH3 | |
| SCHEMBL19441910 | 0.67 | ESR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530186-B2 | Inhibitors for the β-catenin / T-cell factor protein-protein interaction | H. Lee Moffitt Cancer Center and Research Center Institute, Inc. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210017139-A1 | INHIBITORS FOR THE B-CATENIN / T-CELL FACTOR PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017139-A1 | INHIBITORS FOR THE B-CATENIN / T-CELL FACTOR PROTEIN-PROTEIN INTERACTION | CTNNBL1, CTNNB1, APC | KCNH3 4457/4885PDE4A 3833/4885 |
| US-11530186-B2 | Inhibitors for the β-catenin / T-cell factor protein-protein interaction | CTNNB1, CTNNBL1, APC | KCNH3 4519/4885PDE4A 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.